cns-therapeutics
(3)
Axonis Therapeutics
Axonis Therapeutics is a Boston-based, neuro-focused biotechnology company developing first- and best-in-class oral small-molecule medicines that target KCC2, a chloride transporter that acts as the brain's master regulator of inhibitory neurotransmission. Spun out of research from Boston Children's Hospital, Harvard Medical School and Universite Laval, Axonis is advancing its lead candidate AXN-027 - a first-in-class KCC2 potentiator - toward clinical proof of concept in epilepsy, chronic pain and other CNS disorders, backed by an oversubscribed $115 million Series A closed in 2024.
Sensorium Therapeutics
Sensorium Therapeutics is a Boston-based biotechnology company building first-in-class central nervous system (CNS) medicines by decoding nature's neuroactive chemistry with AI. Founded out of Massachusetts General Hospital and Harvard, its proprietary SensAI platform mines more than 50 million curated relationships across ethnopharmacology, chemistry, pharmacology, and clinical outcomes to identify de-risked starting points for new drugs. Its lead program, SNTX-2643, is a rapid-acting precision serotonin modulator for anxiety that received FDA IND clearance in 2025.
Terran Biosciences
Terran Biosciences is a platform biotech developing therapeutics and technologies for neurological and psychiatric disease. It runs one of the industry's largest psychedelic development programs - psilocybin, LSD, MDMA derivatives and novel prodrugs - alongside late-stage schizophrenia assets licensed from Sanofi and Pierre Fabre, GMP psychedelic manufacturing, and NM-101, an FDA-cleared cloud platform for neuromelanin MRI analysis.